Dotinurad
Dotinurad is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against solute carrier family 22 member 12.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
18 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hyperuricemia | D033461 | 1 | 3 | 3 | — | — | 7 | ||
| Gout | D006073 | EFO_0004274 | M10 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 8 | 2 | — | — | — | 10 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hepatic insufficiency | D048550 | 1 | — | — | — | — | 1 | ||
| Renal insufficiency | D051437 | HP_0000083 | N19 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | DOTINURAD |
| INN | dotinurad |
| Description | Dotinurad (Urece) is a drug for the treatment of gout and hyperuricemia. It was developed by Fuji Yakuhin and approved for use in Japan in 2020. The drug is continuing clinical trials by Fortress Biotech and regulatory evaluation for approval in North America and Europe.
|
| Classification | Small molecule |
| Drug class | urate transporter inhibitors |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | O=C(c1cc(Cl)c(O)c(Cl)c1)N1CS(=O)(=O)c2ccccc21 |
Identifiers
| PDB | — |
| CAS-ID | 1285572-51-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4594446 |
| ChEBI ID | — |
| PubChem CID | 51349053 |
| DrugBank | DB16145 |
| UNII ID | 305EB53128 (ChemIDplus, GSRS) |
Target
Agency Approved
SLC22A12
SLC22A12
Organism
Homo sapiens
Gene name
SLC22A12
Gene synonyms
OATL4, URAT1
NCBI Gene ID
Protein name
solute carrier family 22 member 12
Protein synonyms
Organic anion transporter 4-like protein, Renal-specific transporter, RST, solute carrier family 22 (organic anion/cation transporter), member 12, solute carrier family 22 (organic anion/urate transporter), member 12, URAT1, Urate anion exchanger 1, urate anion transporter 1, urate transporter 1, Urate:anion antiporter SLC22A12
Uniprot ID
Mouse ortholog
—
—
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 59 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more